^Fegert JM, Kölch M, Zito JM, Glaeske G, Janhsen K (2006). “Antidepressant use in children and adolescents in Germany”. J. Child Adolesc. Psychopharmacol.16 (1-2): 197–206. doi:10.1089/cap.2006.16.197. PMID 16553540.
^英国国立医療技術評価機構 (2009-08). CG90: Depression in adults (Report). pp. Chapt.1.4.4. http://www.nice.org.uk/CG90.
^ abLinde K, Berner MM, Kriston L (2008). “St John's wort for major depression”. Cochrane Database Syst. Rev.4: CD000448. PMID 18843608. http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD000448/frame.html.
^Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D year=1996. “St John's wort for depression – an overview and meta-analysis of randomised clinical trials”. BMJ313: 253–258. PMID 8704532. http://bmj.bmjjournals.com/cgi/content/full/313/7052/253?view=full&pmid=8704532.
^ abcLinde K, Mulrow CD (2003). “St John's wort for depression (Cochrane Review)”. The Cochrane Library. 3. Chichester, UK: John Wiley & Sons, Ltd..
^Kim HL, Streltzer J, Goebert D (1999). “St. John's wort for depression: a meta-analysis of well-defined clinical trials”. J. Nerv. Ment. Dis.187 (9): 532-538. PMID 10496508.
^Laakmann G, Schüle C, Baghai T, Kieser M (1998). “St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy”. Pharmacopsychiatry31 Suppl 1: 54-59. doi:10.1055/s-2007-979346. PMID 9684948.
^Harrer G, Schmidt U, Kuhn U, Biller A (1999). “Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine”. Arzneimittelforschung.49 (4): 289-296. PMID 10337446.
^Philipp M, Kohnen R, Hiller KO (1999). “Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks”. BMJ319 (7224): 1534-1538. PMID 10591711. http://www.bmj.com/content/319/7224/1534.long.
^米国国立精神衛生研究所 (NIMH). “How is depression detected and treated?”. 2010年10月7日閲覧。
^Hypericum Depression Trial Study Group (2002). “Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial”. JAMA287 (14): 1807-1814. PMID 11939866. http://jama.ama-assn.org/cgi/content/full/287/14/1807.
^Weber W, Vander Stoep A, McCarty RL, Weiss NS, Biederman J, McClellan J (2008). “Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial”. JAMA299 (22): 2633-2641. PMID 18544723. http://jama.ama-assn.org/cgi/content/full/299/22/2633.
^Umek A, Kreft S, Kartnig T, Heydel B (1999). “Quantitative phytochemical analyses of six hypericum species growing in Slovenia”. Planta medica65 (4): 388–90. doi:10.1055/s-2006-960798. PMID 17260265.
^Tatsis EC, Boeren S, Exarchou V, Troganis AN, Vervoort J, Gerothanassis IP, (2007). “Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MS.”. Phytochemistry68 (3): 383–93. doi:10.1016/j.phytochem.2006.11.026. PMID 17196625.
^Schwob I, Bessière JM, Viano J (2002). “Composition of the essential oils of Hypericum perforatum L. from southeastern France”. C. R. Biol.325 (7): 781-785. doi:10.1016/S1631-0691(02)01489-0. PMID 12360846.
^Leuner K, Kazanski V, Müller M, Essin K, Henke B, Gollasch M, Harteneck C, Müller WE (2007). “Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels”. FASEB J.21 (14): 4101–11. doi:10.1096/fj.07-8110com. PMID 1766645.
^Nahrstedt A, Butterweck V (1997). “Biologically active and other chemical constituents of the herb of Hypericum perforatum L.”. Pharmacopsychiatry30 Suppl 2: 129-134. doi:10.1055/s-2007-979533. PMID 9342774.
^Butterweck V (2003). “Mechanism of action of St John's wort in depression : what is known?”. CNS Drugs17 (8): 539–62. doi:10.2165/00023210-200317080-00001. PMID 12775192.
^Müller WE (2003). “Current St John's wort research from mode of action to clinical efficacy”. Pharmacol. Res.47 (2): 101–9. doi:10.1016/S1043-6618(02)00266-9. PMID 12543057.
^Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE (1998). “Hyperforin as a possible antidepressant component of hypericum extracts”. Life Sci.63 (6): 499-510. doi:10.1016/S0024-3205(98)00299-9. PMID 9718074.
^Chatterjee SS, Nöldner M, Koch E, Erdelmeier C (1998). “Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility”. Pharmacopsychiatry31 Suppl 1: 7-15. doi:10.1055/s-2007-979340. PMID 9684942.
^Woelk H (2000). “Comparison of St John's wort and imipramine for treating depression: randomised controlled trial”. BMJ321 (7260): 536–9. doi:10.1136/bmj.321.7260.536. PMC: 27467. PMID 10968813. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC27467/.
^Schrader E (2000). “Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression”. Int. Clin. Psychopharmacol.15 (2): 61–8. doi:10.1097/00004850-200015020-00001. PMID 10759336.
^British Herbal Medicine Association Scientific Committee (1983). British Herbal Pharmacopoeia. West Yorkshire: British Herbal Medicine Association. ISBN 0-903032-07-4.
^ abErnst E, Rand JI, Barnes J, Stevinson C (1998). “Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.)”. Eur. J. Clin. Pharmacol.54 (8): 589-594. doi:10.1007/s002280050519. PMID 9860144.
^Barnes J, Anderson LA, Phillipson JD (2002). Herbal Medicines: A guide for healthcare professionals (2 ed.). London: Pharmaceutical Press. ISBN 0-85369-474-5.
^Singh, Simon and Edzard Ernst (2008). Trick or Treatment: The Undeniable Facts About Alternative Medicine. W. W. Norton & Company. p. 218. ISBN 978-0-393-33778-5.